Ranbaxy gets FDA Approval - 500 Beiträge pro Seite

[Lacocca]

ranbaxy hat heute morgen die zulassungen für doxycycline (infektionen) und metformin hydrochloride (diabetis) für den us markt erhalten.

ranbaxy ist der 9. größte generika hersteller auf dem us markt. zwischen 2000 und 2005 verlieren medikamente (umsatz 35 mrd $) ihren patentschutz!

warum steigt der kurs noch nicht?

[warchild]

Hört sich auf jeden Fall gut an. Bristol-Myers hat allein mit dem einen Medikament (Metformin H.) 2002 einen Umsatz von $297Mio gemacht.

[upstart]

Thursday September 25, 5:11 PM

One may hold on to the Ranbaxy stock
By Tuhin Subhra Kar

Market analyst Sindhu Sameer suggests holding the Ranbaxy stock, if one is invested for the long-term. For the short-term investor he suggested booking profits.

He told CNBC-TV18 that the company has several things going for it, but which will only fructify in the next 1-2 years. He said the company is doing very well in the regulated markets of Europe and America. It is also doing fine in the Est Asian markets.

There is a host of drugs the company is launching, which will put Ranbaxy straight into the speciality segment which is where the cream of the pharma sector is. There are many drugs the company has in its pipeline. It also has a remarkable generic strategy. And it is perhaps the first Indian company to go into basic and fundamental research.

Ranbaxy closed today at Rs 939.15, down 1.1%, with a volume of 461,702 shares traded. It saw an intra-day high of Rs 962 and a low of Rs 934. It touched a year-high of Rs 1075 on September 12 this year and a low of 485.05% on November 7 last year.